Resumen de acción A71 Ascendis Pharma A/S, empresa biofarmacéutica, se centra en el desarrollo de terapias basadas en TransCon para necesidades médicas no cubiertas en Dinamarca, el resto de Europa, Norteamérica e internacionalmente. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Ascendis Pharma A/S Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Ascendis Pharma Precios históricos de las acciones Precio actual de la acción US$138.00 Máximo en las últimas 52 semanas US$147.00 Mínimo de 52 semanas US$99.00 Beta 0.64 Cambio en 1 mes 7.81% Variación en 3 meses 16.95% Cambio de 1 año -4.17% Variación en 3 años 41.54% Variación en 5 años 14.05% Variación desde la OPV 725.21%
Noticias y actualizaciones recientes
Ascendis Pharma A/S (NasdaqGS:ASND) announces an Equity Buyback for $18.25 million worth of its shares. Feb 13
Ascendis Pharma A/S to Report Fiscal Year 2024 Results on Feb 12, 2025 Feb 06 BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court Jan 14
Ascendis Pharma A/S Announces Positive Week 26 Topline Results from New Insights Dec 17
Ascendis Pharma A/S Announces U.S. Food & Drug Administration Accepts for Supplemental Biologics License Application for TransCon HGH for Adult GHD Dec 13
Third quarter 2024 earnings released: €1.72 loss per share (vs €2.88 loss in 3Q 2023) Nov 17 Ver más actualizaciones
Ascendis Pharma A/S (NasdaqGS:ASND) announces an Equity Buyback for $18.25 million worth of its shares. Feb 13
Ascendis Pharma A/S to Report Fiscal Year 2024 Results on Feb 12, 2025 Feb 06 BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court Jan 14
Ascendis Pharma A/S Announces Positive Week 26 Topline Results from New Insights Dec 17
Ascendis Pharma A/S Announces U.S. Food & Drug Administration Accepts for Supplemental Biologics License Application for TransCon HGH for Adult GHD Dec 13
Third quarter 2024 earnings released: €1.72 loss per share (vs €2.88 loss in 3Q 2023) Nov 17
Ascendis Pharma A/S to Report Q3, 2024 Results on Nov 14, 2024 Nov 08
Ascendis Pharma A/S Announces Submission of Supplemental Biologics License Application to FDA for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency Oct 01 Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million. Sep 20
Ascendis Pharma A/S has filed a Follow-on Equity Offering in the amount of $300 million. Sep 19
Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo Sep 16
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (Proc) Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024 Sep 13
New minor risk - Share price stability Sep 05
Second quarter 2024 earnings released: €1.91 loss per share (vs €2.16 loss in 2Q 2023) Sep 04
Ascendis Pharma A/S to Report Q2, 2024 Results on Sep 03, 2024 Aug 28
Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults Aug 13
Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024 Jun 05
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism May 16
New minor risk - Shareholder dilution May 15
Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial May 14
First quarter 2024 earnings released: €2.30 loss per share (vs €1.98 loss in 1Q 2023) May 03
Ascendis Pharma A/S, Annual General Meeting, May 30, 2024 May 03
Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024 Apr 28
Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism Apr 26
Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer Mar 01
Full year 2023 earnings released: €8.55 loss per share (vs €10.40 loss in FY 2022) Feb 08 Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024
Ascendis Pharma A/S Introduces Vision 2030 Jan 08
New minor risk - Profitability Dec 22
Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH Dec 21
Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency Dec 19
FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism Dec 12
Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism Nov 21
Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA Nov 17
New minor risk - Profitability Nov 13
New major risk - Negative shareholders equity Nov 10
New major risk - Negative shareholders equity Nov 08
Third quarter 2023 earnings released: €2.88 loss per share (vs €3.03 loss in 3Q 2022) Nov 08
Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023 Oct 27
Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting Oct 05
Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency Sep 25
Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency Sep 16
Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism Sep 15
Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH Sep 07
Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023 Aug 16
Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023 Jun 19
Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023 Jun 14
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates Jun 01
Ascendis Pharma A/S, Annual General Meeting, May 30, 2023 May 04
Full year 2022 earnings released: €10.40 loss per share (vs €7.00 loss in FY 2021) Feb 18
Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023 Feb 08
Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Expanded Access Program for Its Investigational Parathyroid Hormone Replacement Therapy, Transcon PTH Dec 06
Ascendis Pharma Submits Marketing Authorization Application to the European Medicines Agency for Transcon™ PTH in Adult Patients with Hypoparathyroidism Nov 15
TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 µg/kg/week, in Ascendis Pharma’s Phase 2 ACcomplisH Trial of Children with Achondroplasia Aged 2 to 10 Years Nov 14
Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of TransCon™ TLR7/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022 Nov 12
Third quarter 2022 earnings released: €3.03 loss per share (vs €1.47 loss in 3Q 2021) Nov 03
Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) PTH in Adult Patients with Hypoparathyroidism Nov 01
Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT-101, A Phase 1/2 Clinical Trial of TransCon TLR7/8 Agonist in Solid Tumors Oct 04
Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directors Sep 14
Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial Sep 13
Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adult Patients with Hypoparathyroidism Sep 01
Second quarter 2022 earnings released: €1.46 loss per share (vs €2.50 loss in 2Q 2021) Aug 12 Ascendis Pharma A/S Announces Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon HGH in China Consistent
First quarter 2022 earnings released: €2.21 loss per share (vs €1.17 loss in 1Q 2021) May 13
Ascendis Pharma A/S, Annual General Meeting, May 30, 2022 May 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 05
Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency Jan 14
Ascendis Pharma A/S to Provide an Update on Two of Its Investigational Endocrinology Rare Disease Development Programs Dec 15
Third quarter 2021 earnings released: €1.47 loss per share (vs €2.31 loss in 3Q 2020) Nov 12
Ascendis Pharma A/S Announces Mean Bone Mineral Density Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks Sep 24
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 ß/? Clinical Program Sep 08
Ascendis Pharma Announces U.S. Food and Drug Administration Approval of SKYTROFA Aug 26
Second quarter 2021 earnings released: €2.50 loss per share (vs €1.97 loss in 2Q 2020) Aug 26
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Notifies Information Submitted in Connection with the FDA's Ongoing Review of the Biologics License Application for Lonapegsomatropin Jun 15
VISEN Pharmaceuticals Obtains the Investigational New Drug Approval from the Center for Drug Evaluation of the National Medical Products Administration for the Phase III China Clinical Trial of TransCon Parathyroid Hormone Jun 04
First quarter 2021 earnings released: €1.17 loss per share (vs €1.32 loss in 1Q 2020) May 28
Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan May 13
Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and A Well-Tolerated Safety Profile May 11
Full year 2020 earnings released: €8.28 loss per share (vs €4.69 loss in FY 2019) Mar 13
Revenue misses expectations Mar 13
New 90-day low: €120 Mar 06
New 90-day low: €126 Jan 23
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate Transcon™ TLR7/8 Agonist Clinical Program Dec 31
New 90-day high: €150 Dec 16
Ascendis Pharma A/S Announces Michael Wolf Jensen Does Not Stand for Re-Election to Its Board Dec 15
Third quarter 2020 earnings released: €2.31 loss per share Nov 13
Revenue beats expectations Nov 13
Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases Nov 04
New 90-day high: €140 Nov 02
New 90-day high: €136 Oct 05 Rentabilidad de los accionistas A71 DE Biotechs Mercado DE 7D 20.0% -11.3% 3.0% 1Y -4.2% -15.0% 19.3%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: A71 superó a la industria German Biotechs, que obtuvo un rendimiento del -15% el año pasado.
Rentabilidad vs. Mercado: A71 obtuvo unos resultados inferiores a los del mercado German, que fueron del 19.3% el año pasado.
Volatilidad de los precios Is A71's price volatile compared to industry and market? A71 volatility A71 Average Weekly Movement 7.0% Biotechs Industry Average Movement 8.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.5%
Precio estable de las acciones: A71 no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado German.
Volatilidad a lo largo del tiempo: La volatilidad semanal de A71 (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Ascendis Pharma A/S, empresa biofarmacéutica, se centra en el desarrollo de terapias basadas en TransCon para necesidades médicas no cubiertas en Dinamarca, el resto de Europa, Norteamérica e internacionalmente. La empresa ofrece SKYTROFA para el tratamiento de pacientes pediátricos con deficiencia de la hormona del crecimiento; y YORVIPATH, una inyección subcutánea una vez al día para el tratamiento de adultos con hipoparatiroidismo crónico. También desarrolla una cartera de tres candidatos independientes para enfermedades raras endocrinológicas en fase de desarrollo clínico, y se centra en el avance de candidatos terapéuticos oncológicos.
Mostrar más Resumen de fundamentos de Ascendis Pharma A/S ¿Cómo se comparan los beneficios e ingresos de Ascendis Pharma con su capitalización de mercado? Estadísticas fundamentales de A71 Capitalización bursátil €8.25b Beneficios(TTM ) -€378.08m Ingresos (TTM ) €363.64m
24.6x Ratio precio-ventas (PS)
-23.7x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de A71 Ingresos €363.64m Coste de los ingresos €44.26m Beneficio bruto €319.38m Otros gastos €697.47m Beneficios -€378.08m
Últimos beneficios comunicados
Dec 31, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -6.32 Margen bruto 87.83% Margen de beneficio neto -103.97% Ratio deuda/patrimonio -722.4%
¿Cómo se ha desempeñado A71 a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/02/18 21:31 Precio de las acciones al final del día 2025/02/18 00:00 Beneficios 2024/12/31 Ingresos anuales 2024/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github .
Fuentes analistas Ascendis Pharma A/S está cubierta por 22 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Tazeen Ahmad BofA Global Research Michelle Gilson Canaccord Genuity Alethia Young Cantor Fitzgerald & Co.
Mostrar 19 más analistas 
